Piyasa kapalı· · AUD · Veriler gecikmeli olabilir
Fiyatlar gecikmeli olabilir ve yalnızca bilgilendirme amaçlıdır - yatırım tavsiyesi değildir.
Australia’s cash rate is now at a 15 year high of 4.6%, which puts real pressure on slower growing businesses. Faster earnings growth can matter more when money is this expensive, because the market often rewards companies that can still expand profits while others struggle. This article highlights three Australian stocks from a high growth opportunity screen that analysts expect to deliver solid earnings momentum and maintain broadly healthy balance sheets. The three stocks below are only a...
Rising global bond yields are lifting borrowing costs and pressuring richly priced growth stories. Yet Australian companies with solid balance sheets and credible earnings expansion forecasts still attract attention. That mix of resilience and growth potential can be hard to find, which creates a real fear of missing out when it appears. This article highlights three stocks from a high quality Australian growth screener that fit that profile. The three stocks below are just a starting sample...
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.comNEW YORK, Sept. 18, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, announced the presentations from the September 17th Life Sciences Virtual Investor Forum are available for on-demand viewing. The event featured live presentations from executives representing innovative clinical-stage and commercial companies across the life sciences sector. REGIS
Company executives will discuss their business strategies, provide updates on recent developments, and answer questions live from investors.NEW YORK, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the upcoming Life Sciences Virtual Investor Forum taking place on September 17, 2026. REGISTER HERE Individual investors, institutional investors, advisors, and analysts are invited to attend. It is rec
The companies pair-up aims to streamline health institutions' ability to manage lung care paradigms end-to-end.
Azra AI, a healthcare enterprise platform that accelerates patient identification and care coordination, and 4DMedical (ASX: 4DX), a global leader in quantitative lung imaging analytics, today announce a strategic OEM and reseller partnership. Under the agreement, 4DMedical will resell Azra AI's real-time patient-identification platform to its health system customers, giving them a single, coordinated path from an incidental finding or critical condition to the specialized care a patient needs.
4DMedical Limited (ASX: 4DX), the global leader in advanced respiratory imaging, today announced that CT:VQ™ technology has Therapeutic Goods Administration (TGA) approval and is included on the Australian Register of Therapeutic Goods (ARTG)—enabling commercial deployment across Australia.
Company Executives Share Strategic Vision and Engage with Investors Live at VirtualInvestorConferences.comNEW YORK, June 23, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the Life Sciences Virtual Investor Forum, taking place June 24th & 25th, 2026. Individual investors, institutional investors, advisors, and analysts are invited to attend. REGISTER HERE Investors are encouraged to pre-register and run th
SAN ANTONIO, June 16, 2026--bioAffinity Technologies announces joint webinar with Philips and 4DMedical on diagnostic and imaging technologies to support lung health in veterans.
4DMedical (ASX:4DX) has signed a contract with GlaxoSmithKline to supply quantitative lung imaging analytics. The agreement focuses on using 4DMedical’s technology in GSK’s drug development programs. The deal marks further commercial traction for 4DMedical’s proprietary respiratory imaging platform with a major global pharmaceutical company. 4DMedical focuses on respiratory imaging analytics, aiming to give drug developers more granular insight into lung function than traditional scans...
NEW YORK, April 24, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced presentations from the April 23rd AI & Technology Virtual Investor Conference are available for on-demand viewing. Investors, advisors, and analysts can now access presentations at their convenience. REGISTER AND VIEW PRESENTATIONS HERE The company presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may download investor ma
Company executives will discuss their business strategies, provide updates on recent developments, and answer questions live at VirtualInvestorConferences.comNEW YORK, April 20, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the AI & Technology Virtual Investor Conference to be held April 23rd, 2026. The event will feature presentations from senior executives of companies operating across the artificial in
4DMedical Limited (ASX:4DX), the global leader in cardiothoracic imaging software, announces that its latest imaging technology, CT:VQ™ has received CE Mark certification for commercial use in the European Union. 4DMedical will quickly launch commercial deployment of CT:VQ across one of the world's largest respiratory imaging markets.
4DMedical Limited ( ASX:4DX ) is possibly approaching a major achievement in its business, so we would like to shine...
Üçüncü taraf yayıncıların bu şirket hakkındaki son başlıkları; Makkler'in kendi editoryal içeriğinden ayrı tutulur ve dış kaynağa yönlendirir. Başlıkların doğruluğu ilgili yayıncının sorumluluğundadır.